Importer of Controlled Substances; Notice of Application, 44858-44859 [E7-15498]
Download as PDF
<![CDATA[
44858
Federal Register / Vol. 72, No. 153 / Thursday, August 9, 2007 / Notices
page reproduction cost) payable to the
U.S. Treasury or, if by e-mail or fax,
forward a check in that amount to the
Consent Decree Library at the stated
address.
Ronald G. Gluck,
Assistant Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
[FR Doc. 07–3867 Filed 8–8–07; 8:45 am]
BILLING CODE 4410–15–M
DEPARTMENT OF JUSTICE
mstockstill on PROD1PC66 with NOTICES
Notice of Lodging of Settlement
Agreement Under the Comprehensive
Environmental Response,
Compensation, and Liability Act
Notice is hereby given that on July 26,
2007, a proposed settlement agreement
in In re Marcal Paper Mills, Inc. Case
No. 06–21886(MS), was lodged with the
United States Bankruptcy Court for the
District of New Jersey.
The proposed settlement agreement
resolves claims asserted by the United
States, on behalf of the United States
Environmental Protection Agency
(‘‘EPA’’), the United States Department
of Interior (‘‘DOI’’), and the National
Oceanic and Atmospheric
Administration of the United States
Department of Commerce (‘‘NOAA’’),
against the debtor Marcal Paper Mills,
Inc., under the Comprehensive
Environmental Response,
Compensation, and Liability Act
(‘‘CERCLA’’), 42 USC 9601 et seq. The
claims were contained in a Proof of
Claim filed with the Court on June 14,
2007 and sought to recover response
costs incurred and to be incurred and
natural resource damages at the
Diamond Alkali Superfund Site in New
Jersey. The proposed settlement
agreement stipulates that the United
States’ unsecured claim shall be treated
as an allowed claim in the amount of
$3,000,000.
The Department of Justice will receive
for a period of thirty (30) days from the
date of this publication comments
relating to the proposed settlement
agreement. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and either e-mailed
to pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to In re
Marcal Paper Mills, Inc. D.J. Ref. 90–11–
3–07683/5.
During the public comment period,
the Settlement Agreement may also be
examined on the following Department
of Justice Web site, https://
VerDate Aug<31>2005
18:25 Aug 08, 2007
Jkt 211001
www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
proposed Settlement Agreement may
also be obtained by mail from the
Consent Decree Library, P.O. Box 7611,
U.S. Department of Justice, Washington,
DC 20044–7611 or by faxing or emailing a request to Tonia Fleetwood
(tonia.fleetwood@usdoj.gov), fax no.
(202) 514–0097, phone confirmation no.
(202) 514–1547. In requesting a copy
from the Consent Decree Library, please
enclose a check in the amount of $2.50
(25 cents per page reproduction cost)
payable to the ‘‘U.S. Treasury’’ or, if by
e-mail or fax, forward a check in that
amount to the Consent Decree Library at
the stated address.
Ronald G. Gluck
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division, U.S. Department
of Justice.
[FR Doc. 07–3865 Filed 8–8–07; 8:45 am]
BILLING CODE 4410–15–M
DEPARTMENT OF JUSTICE
Notice of Lodging of Partial Consent
Decree Under the Clean Water Act
Notice is hereby given that on July 31,
2007, a proposed Final Consent Decree
in United States v. City of San Diego,
Civil Action No. 01–CV–0550B (POR),
was lodged with the United States
District Court for the Southern District
of California. The United States’ action
is consolidated with San Diego
Baykeeper, et al. v. City of San Diego
and State of California v. City of San
Diego.
In this action the United States seeks
penalties and injunctive relief to
address sanitary sewer overflows and
other violations of the Clean Water Act
and the City of San Diego’s National
Pollutant Discharge Elimination System
Permit. The Final Consent Decree
includes requirements that have already
been initiated but not yet completed
under previous settlements.
This Final Consent Decree requires
the City to continue to take action to
create programs and maintain and
upgrade the sewer infrastructure to
include, among other things; (1)
Comprehensive cleanings of the
collection system; (2) inspection of
manholes; (3) completion of specified
capital projects; (4) repair, rehabilitation
or replacement of pipeline; (5)
completion of canyon economic and
environmental analyses; (6) securing of
manhole covers; and (7) completed
CCTV inspections. Further, the Final
Consent Decree commits the City to
implement an additional six year
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
program to improve the City’s system
and reduce spills.
The Department of Justice will receive
for a period of thirty (30) days from the
date of this publication comments
relating to the Final Consent Decree.
Comments should be addressed to the
Assistant Attorney General,
Environment and Natural Resources
Division, and either e-mailed to
pubcommentees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to United
States v. City of San Diego, D.J. Ref. 90–
5–1–1–4364/1.
The Final Consent Decree may be
examined at U.S. EPA Region 9, 75
Hawthorne Street, San Francisco,
California 94105. During the public
comment period, the Final Consent
Decree, may also be examined on the
following Department of Justice Web
site, to https://www.usdoj.gov/enrd/
ConsentlDecrees.html. A copy of the
Final Consent Decree may also be
obtained by mail from the Consent
Decree Library, P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611 or by faxing or e-mailing a
request to Tonia Fleetwood
(tonia.fleetwood@usdoj.gov), fax no.
(202) 514–0097, phone confirmation
number (202) 514–1547. In requesting a
copy from the Consent Decree Library,
please enclose a check in the amount of
$16.50 (25 cents per page reproduction
cost) payable to the U.S. Treasury or, if
by e-mail or fax, forward a check in that
amount to the Consent Decree Library at
the stated address.
Ellen Mahan,
Deputy Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
[FR Doc. 07–3868 Filed 8–8–07; 8:45 am]
BILLING CODE 4410–15–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on June
E:\FR\FM\09AUN1.SGM
09AUN1
Federal Register / Vol. 72, No. 153 / Thursday, August 9, 2007 / Notices
mstockstill on PROD1PC66 with NOTICES
15, 2007, Alcan Packaging-Bethlehem,
2400 Baglyos Circle, Bethlehem,
Pennsylvania 18020, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Nabilone (7379) a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance for
packaging and distribution.
Any bulk manufacturer who is
presently, or are applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 2401 Jefferson
Davis Highway, Alexandria, Virginia
22301; and must be filed no later than
September 10, 2007.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: July 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–15498 Filed 8–8–07; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
18:25 Aug 08, 2007
Jkt 211001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on June
18, 2007, Almac Clinical Services Inc.,
(ACSI), 2661 Audubon Road, Audubon,
Pennsylvania 19403, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Oxycodone (9143) ........................
Fentanyl (9801) ............................
II
II
The company plans to import small
quantities of the listed controlled
substance in dosage form to conduct
clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 2401 Jefferson
Davis Highway, Alexandria, Virginia
22301; and must be filed no later than
September 10, 2007.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
44859
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: July 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–15512 Filed 8–8–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such substances, provide manufacturers
holding registrations for the bulk
manufacture of the substance an
opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on May 17,
2007, Aptuit (Allendale), Inc., 75
Commerce Drive, Allendale, New Jersey
07401, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
basic class of controlled substance for
clinical trials and research.
Any manufacturer who presently, or
is applying to be, registered with DEA
to manufacture such basic class of
controlled substance may file comments
or objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537; or any being sent via express
mail should be sent to, Drug
E:\FR\FM\09AUN1.SGM
09AUN1
]]>Agencies
[Federal Register Volume 72, Number 153 (Thursday, August 9, 2007)]
[Notices]
[Pages 44858-44859]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-15498]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II and prior to issuing a
registration under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on June
[[Page 44859]]
15, 2007, Alcan Packaging-Bethlehem, 2400 Baglyos Circle, Bethlehem,
Pennsylvania 18020, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as an importer of Nabilone (7379)
a basic class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance for
packaging and distribution.
Any bulk manufacturer who is presently, or are applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC 20537, or any being sent via express mail should be sent
to Drug Enforcement Administration, Office of Diversion Control,
Federal Register Representative (ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be filed no later than September
10, 2007.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e) and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975 (40 FR 43745-46), all applicants
for registration to import a basic class of any controlled substances
in schedule I or II are and will continue to be required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: July 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-15498 Filed 8-8-07; 8:45 am]
BILLING CODE 4410-09-P
